Use of thiol-containing compound for the stabilization of a flavanonol

Thiol-containing compounds stabilize flavanonols in topical compositions, addressing the limitations of traditional stabilizers by enhancing stability and safety, ensuring effective preservation of flavanonols.

WO2026234291A1PCT designated stage Publication Date: 2026-11-12DSM IP ASSETS BV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/EP2026/063542
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2025-05-09
Filing Date
2026-05-11
Publication Date
2026-11-12

AI Technical Summary

Technical Problem

Existing stabilizers for flavanonols, such as sulfites, bisulfites, and disulfites, pose risks of allergic reactions and pungent smells, necessitating the need for alternative stabilizers that are safer and more effective.

Method used

Using thiol-containing compounds, particularly thiol-containing amino acids and peptides, to stabilize flavanonols in topical compositions, achieving a molar or weight ratio of 1:50 to 5:1 with flavanonols, thereby enhancing stability and reducing degradation.

Benefits of technology

The use of thiol-containing compounds results in a more stable and effective topical composition, preserving the efficacy of flavanonols like dihydromyricetin, while eliminating the drawbacks of traditional stabilizers.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure IMGF000009_0001
    Figure IMGF000009_0001
  • Figure IMGF000011_0001
    Figure IMGF000011_0001
  • Figure IMGF000011_0002
    Figure IMGF000011_0002
Patent Text Reader

Abstract

A use of a thiol-containing compound for the stabilization of a flavanonol in a topical composition, preferably a composition for use on keratinous tissue such as the skin, scalp or hair.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] 2025P00142WC

[0002] NOVEL USE AND NOVEL COMPOSITION

[0003] TECHNICAL FIELD OF THE INVENTION

[0004]

[0001] The present invention relates to a novel use of certain thiols as a stabilizer for a topical composition comprising flavanonol and the composition so obtained.

[0005] BACKGROUND OF THE INVENTION

[0006]

[0002] Flavanonols are a flavonoid subclass of polyphenolic compounds that are increasingly valued for their applications in cosmetic industry. Flavanonols that recently gained special attention include Dihydromyricetin (also known as Ampelopsin), Taxifolin and Aromadendrin.

[0007]

[0003] Taxifolin (also known as dihydroquercetin) is of increasing interest due to its beneficial characteristics in skincare. For example, Micek et al, in their article titled “Taxifolin as a Promising Ingredient of Cosmetics for Adult Skin”, published in Antioxidants, 2021, 10, as item 1625, studied and concluded that, in addition to its good anti-oxidant characteristics, taxifolin may for example have an advantageous effect skin viscoelasticity.

[0008]

[0004] WO2025021355A1 describes that Dihydromyricetin has demonstrated epigenetic activity. Epigenetically active compounds are believed to be able to modulate gene expression through histone modifications and DNA methylation, promoting skin rejuvenation and protection.

[0009]

[0005] US20200085956A1 refers to cosmetic compositions comprising Aromadendrin.

[0010]

[0006] Unfortunately polyphenols are susceptible to oxidation and thermal degradation, as described by Cao et al in their article titled “Available technologies on improving the stability of polyphenols in food processing”, published in Food Frontiers, 2021, vol. 2, pages 109-139. Several approaches to stabilize the compounds have been developed.

[0011]

[0007] However, as indicated by Xiao et al, in their article titled “Recent advances on the stability of dietary polyphenols”, published in eFood, 2022; vol. 3:e21 , stabilization effects involving polyphenols within a complex matrix can often be unpredictable. It is stated thatfor example ascorbic acid can increase the stability of flavonols but may reduce the stability of anthocyanins and phenolic acids.

[0012]

[0008] CN113831995 describes a composition for enhancing the content stability of active ingredients of a prepared wine, wherein the composition may comprise yeast extract, grape seed extract and L-cysteine. CN113831995 does not describe or refer to any cosmetic compositions or applications.

[0013]

[0009] Cosmetic products such as the "Total White Underarm Cream", marketed by Cosmonation comprise ingredients such as dihydromyricetin, sodium bisulfite and oxidized glutathione. However, the function of each of these ingredients is not disclosed.

[0014]

[0010] CN104522217 describes a vine tea extract prepared by a process including a step of adding a flavones protective agent into an aqueous solution during water extraction of the vine tea. CN104522217 does not describe or refer to any cosmetic compositions or applications.

[0015]

[0011] US2022 / 257561 describes a composition for improving wellness of a human, the composition comprising a flavonoid and a prodrug of cysteine.

[0016]

[0012] WO2018 / 134714 describes a cosmetic skin care composition comprising: dihydromyricetin, niacinamide, and a pH modifier on a cosmetically acceptable vehicle.

[0017]

[0013] US2002 / 123460 describes compositions containing oil-soluble and / or water-soluble oxygen-labile species comprising oil-soluble or water-soluble oxygen-labile species and one or more stabilizer compounds selected from the group consisting of thiocontaining compounds and glycoproteins.

[0018]

[0014] Above mentioned WO2025 / 021355 describes cosmetic and / or dermatological preparations containing combinations of dihydromyricetin and one or more sulphites and / or bisulfites and / or disulfites. WO2025 / 021355A1 describes that cosmetic or dermatological preparations containing combinations of dihydromyricetin and one or more sulfites and / or bisulfites and / or disulfites would be excellently protected against oxidative influences.

[0019]

[0015] However, such sulfites, bisulfites and / or disulfites can have serious disadvantages when used in a cosmetic or dermatological preparation. Susceptible individuals maydevelop allergic reactions, including headaches or respiratory issues, following contact with such (bi)sulfites. Therefore products containing bisulphites often need to be labelled accordingly. In addition, there exists a risk of the formation of sulphur dioxide and the resulting pungent smell.

[0020]

[0016] It would therefore be an advancement in the art to provide suitable alternative stabilizers for topical formulations containing flavanonols, which alternative stabilizers have less of the above disadvantages.

[0021] SUMMARY OF THE INVENTION

[0022]

[0001] Inventors have now surprisingly found that by using a thiol-containing compound as a stabilizer for a topical composition comprising flavanonol, a more stable composition can be obtained.

[0023]

[0002] Accordingly, in a first aspect, the invention provides a use of thiol-containing compound for the stabilization of a flavanonol in a topical composition. More preferably the invention provides a use of a thiol-containing amino acid and / or a thiol-containing peptide for the stabilization of a flavanonol, preferably dihydromyricetin, in a topical composition. Preferably the topical composition is a composition for use on keratinous tissue such as the skin, scalp or hair.

[0024]

[0003] More preferably the invention provides a use of a thiol-containing compound for stabilizing dihydromyricetin in a topical composition for epigenetic treatment of the skin, preferably wherein the topical composition comprises an amount of dihydromyricetin in the range from equal to or more than 0.001 wt. %, more preferably from equal to or more than 0.01 wt. % to equal to or less than 10 wt. %, more preferably to equal to or less than 1 wt. %, based on the total weight of the composition.

[0025]

[0004] In a second aspect, the invention provides a topical composition comprising a) a flavanonol; and

[0026] b) a thiol-containing compound,wherein preferably the composition comprises the flavanonol and the thiol-containing compound in a molar ratio of flavanonol to thiol-containing compound in the range from equal to or more than 1 :50 to equal to or less than 5:1.

[0027]

[0005] In addition, the invention provides a topical composition comprising

[0028] a) a flavanonol; and

[0029] b) a thiol-containing compound,

[0030] wherein preferably the composition comprises the flavanonol and the thiol-containing compound in a weight ratio of flavanonol to thiol-containing compound in the range from equal to or more than 1 :50 to equal to or less than 5: 1.

[0031]

[0006] More preferably the invention provides a topical composition comprising a) dihydromyricetin; and

[0032] b) a thiol-containing compound,

[0033] wherein the topical composition comprises an amount of dihydromyricetin in the range from equal to or more than 0.001 wt. %, more preferably from equal to or more than 0.01 wt. % to equal to or less than 10 wt. %, more preferably to equal to or less than 1 wt. %, based on the total weight of the composition,

[0034] wherein preferably the composition comprises the dihydromyricetin and the thiol-containing compound in a weight ratio of dihydromyricetin to thiol-containing compound in the range from equal to or more than 1 :50 to equal to or less than 5:1.

[0035]

[0007] As illustrated by the examples, the above use and composition may advantageously lead to a better stability and less degradation of a flavanonol such as dihydromyricetin. The above use and composition may therefore advantageously also better preserve efficacy of dihydromyricetin as an epigenetic active ingredient. Therefore, in a third aspect, the invention provides a method comprising the step of topically applying to a skin in need thereof a topical composition comprising:

[0036] - dihydromyricetin as an epigenetic active ingredient; and

[0037] - a thiol-containing compound.

[0038]

[0008] Further preferences are provided herein below and in the examples.DESCRIPTION OF THE FIGURES

[0039]

[0009] The invention is illustrated with the help of the following figures:

[0040] Figure 1. Photograph of the solutions at day 8 after preparation, including from left to right the flasks with (1) No stabilizer, (2) sodium metabisulfite, (3) glutathione (nonoxidized) , (4) ascorbic acid, (5) cysteine.

[0041] DETAILED DESCRIPTION OF THE INVENTION DEFINITIONS

[0042]

[0010] Unless defined otherwise or clearly indicated by context, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art.

[0043]

[0011] The articles “a” and “an” are used herein to refer to one or to more than one (i.e. to one or at least one) of the grammatical object of the article. By way of example, “an element” may mean one element or more than one element. When referring to a noun (e.g. a compound, an additive, etc.) in the singular, the plural is meant to be included. Thus, when referring to a specific moiety, e.g. a "compound", this means "at least one" of that compound, e.g. "at least one compound", unless specified otherwise.

[0044]

[0012] Throughout the present specification and the accompanying claims, all transitional phrases such as ‘comprising,’ ‘including,’ ‘carrying,’ ‘having,’ ‘containing,’ ‘involving,’ ‘holding,’ ‘composed of’, and variations such as "comprises", "comprise", "includes" and "include" are to be interpreted inclusively and to be understood to be open-ended, i.e., to mean including but not limited to. That is, these words are intended to convey the possible inclusion of other elements or integers not specifically recited, where the context allows. Only the transitional phrases ‘consisting of’ and ‘consisting essentially of’ shall be closed or semi-closed transitional phrases, respectively.

[0045]

[0013] The term 'consisting essentially of' as used herein means that the total amount of the listed ingredients ideally sums up to 100 wt. % (weight percent). It is however not excluded that small amount of impurities derived from the ingredients and / or the production process may be present.

[0014] Throughout this application, the term "about" is used to indicate that a value includes the standard deviation of error for the device or method being employed to determine the value.

[0046]

[0015] As used herein, the terms “% by weight”, “wt. %”, “weight percentage”, or “percentage by weight” are used interchangeably. The same applies mutatis mutandis to the terms “% by volume”, “vol. %”, “vol. percentage”, or “percentage by volume”, respectively to the terms “% by mol”, “mol %”, “mol percentage”, or “percentage by mol”.

[0047]

[0016] Unless explicitly indicated otherwise, the various embodiments of the invention described herein can be cross-combined. That is, each alternative and / or embodiment so defined herein may be combined with any other alternative and / or embodiment herein, and this for each variant unless clearly indicated to the contrary or clearly incompatible when the value range of a same parameter is disjoined. In particular, any feature indicated as being preferred or advantageous may be combined with any other feature or features indicated as being preferred or advantageous.

[0048]

[0017] The terms "cosmetic composition", “cosmetic product” and “cosmetic preparation” are used interchangeably herein and refer in the present document to a composition suitable for cosmetic purposes. Suitably a cosmetic composition is herein understood to be a composition for cosmetic, that is, non-therapeutic use. More preferably the terms "cosmetic composition", “cosmetic product” and “cosmetic preparation” refer in the present document to a composition which is applied to the surface of a mammalian keratinous tissue. Such "cosmetic composition", “cosmetic product” respectively “cosmetic preparation” can comprise or consist of those cosmetic compositions as defined under the heading "Kosmetika" in Rdmpp Lexikon Chemie, 10th edition 1997, Georg Thieme Verlag Stuttgart, New York as well as to cosmetic compositions as disclosed in A. Domsch, "Cosmetic Compositions", Verlag fur chemische Industrie (ed. H. Ziolkowsky), 4thedition, 1992. More preferably the "cosmetic composition", “cosmetic product” respectively “cosmetic preparation” is a composition, product, respectively preparation, that can be topically applied to mammalian keratinous tissue such as e.g. human skin, scalp or hair (including eyelashes, the eyebrows, the nails or the lips). Hence,the "cosmetic composition", “cosmetic product” respectively “cosmetic preparation” is preferably a topical composition, product, respectively preparation. By a topical composition (also referred to herein as a “topical product” or “topical preparation”) is herein understood a composition for, preferably external, use on keratinous tissue such as the skin, scalp or hair.

[0049]

[0018] The term “keratinous tissue" as used in this document refers to tissue containing keratine, more preferably it refers to the skin (including the scalp), head hair, eyelashes, eyebrows, bodily hairs, nails and / or lips. More preferably, the keratinous tissue is the skin, scalp or hair.

[0050]

[0019] The terms “carrier”, “carrier component” and “carrier ingredient” are used interchangeably herein. The term “carrier” is preferably understood to refer to an ingredient in a composition that can serve as a medium to deliver an active ingredient and / or other ingredients to an intended site of action. Preferably such a carrier may help to stabilize, distribute, and / or facilitate the application of such an active ingredient. The carrier is preferably a cosmetically acceptable carrier. By a cosmetically acceptable carrier is herein preferably understood a carrier that is accepted for cosmetic purposes. More preferably the carrier is a carrier suitable for topical application to a keratinous tissue, preferably having good aesthetic properties, preferably compatible with the actives present in the composition, and / or preferably the carrier will not cause any unreasonable safety or toxicity concerns. Such carriers are well-known to one of ordinary skill in the art and can include one or more compatible liquid(s) or solid filler diluent(s), excipient(s), additive(s) or vehicle(s) which are suitable for application to skin, scalp and / or hair.

[0051]

[0020] The terms “active ingredient”, “active agent” and simply “agent” or “active” are used interchangeably herein. These terms preferably refer to a substance or ingredient that has a specific physiological or biochemical effect on a keratinous tissue such as the skin, scalp or hair. Such agents may suitably be included in a composition, preferably a cosmetic composition, for their ability to target and address specific concerns or provide benefits, such as for example moisturizing, anti-aging, brightening, soothing, orprotecting. Active agents can thus advantageously be key ingredients responsible for the claimed efficacy of a cosmetic composition.

[0052]

[0021] The terms “helper ingredient”, “helper component” and “excipient” are used interchangeably herein. These terms preferably refer to a substance or ingredient used in a composition to serve as an aid in the processing, stability, and / or delivery of the active ingredients. Excipients can for example be used to ensure the proper form, consistency, and / or stability of a product. Examples of the functions of excipients thus include stabilizing, binding, filling, preserving, facilitating thereof and / or aiding in the delivery of active ingredients. Preferred examples of excipients include stabilizers and / or preservatives.

[0053] FLAVANONOLS

[0054]

[0022] Flavanonols are a subclass of flavonoids. Flavanonols can suitably be characterized by a 3-hydroxyflavanone backbone as illustrated in structural formula (I), wherein the rings may conveniently be numbered “A”, “B” and “C”

[0055]

[0056]

[0023] Such 3-hydroxyflavanone backbone may be substituted with one or more substituents.

[0057]

[0024] The group of flavanonols has increased applicability in cosmetic industry. In the aspects of the present invention such flavanonols may be advantageously used as an active agent in a topical composition. For example, the flavanonol may advantageously be an anti-oxidation agent or an anti-aging agent.

[0058]

[0025] In all aspects of this invention, the flavanonol preferably comprises a total number of hydroxy groups (including the 3-hydroxy group of the backbone) in the range fromequal to or more than 2 to equal to or less than 8, more preferably in the range from equal to or more than 3 to equal to or less than 7, most preferably in the range from equal to or more than 4 to equal to or less than 6.

[0059]

[0026] Preferably the flavanonol is a flavanonol comprising at least a hydroxy group at the positions 3, 5 and 7 of the molecule.

[0060]

[0027] Preferably the flavanonol is a flavanonol wherein the “A” ring is substituted with a total number of hydroxy groups in the range from equal to or more than 1 to equal to or less than 4, more preferably in the range from equal to or more than 1 to equal to or less than 3 and most preferably in the range from equal to or more than 1 to equal to or less than 2. Preferably the flavanonol is a flavanonol wherein the “A” ring is substituted with a hydroxy group at the positions 5 and / or 7. More preferably the flavanonol is a flavanonol wherein the “A” ring is substituted with a hydroxy group at the positions 5 and 7.

[0061]

[0028] Preferably the flavanonol is a flavanonol wherein the “B” ring is substituted with a total number of hydroxy groups in the range from equal to or more than 1 to equal to or less than 5, more preferably in the range from equal to or more than 1 to equal to or less than 4 and most preferably in the range from equal to or more than 1 to equal to or less than 3. Preferably the flavanonol is a flavanonol wherein the “B” ring is substituted with a hydroxy group at the positions 3’, 4’ and / or 5’. More preferably the flavanonol is a flavanonol wherein the “B” ring is substituted with a hydroxy group at least at the position 4’. Most preferably the flavanonol is a flavanonol wherein the “B” ring is substituted with a hydroxy group at the positions 3’, 4’ and 5’.

[0062]

[0029] Preferably the flavanonol in all aspects of the invention is a flavanonol selected from the group consisting of Dihydromyricetin, Taxifolin and Aromadendrin. Most preferably the flavanonol is Dihydromyricetin.

[0063]

[0030] Dihydromyricetin (herein also abbreviated as “DHM”) is a hexahydroxyflavan-4-one having the structural formula (IA).

[0064]

[0065]

[0031] Dihydromyricetin can also be referred to as 3,3',4',5,5',7-Hexahydroxyflavan-4- one, as 3,5,7-Trihydroxy-2-(3,4,5-trihydroxy)-2,3-dihydro-4 / - / -1-benzopyran-4-one or as Ampelopsin.

[0066]

[0032] In all aspects of the invention, such dihydromyricetin may be chemically or microbiologically produced or may be derived or obtained from a natural source. Examples of natural sources from which the dihydromyricetin can be extracted include Hovenia species such as Hovenia dulcis (also referred to as the Oriental raisin tree); Ampelopsis species such as Ampelopsis japonica, Ampelopsis megalophylla, and Ampelopsis grossedentata', Cercidiphyllum species such as Cercidiphyllum japonicunr, Rhododendron species such as Rhododendron cinnabarinunT, some Pinus species; Cedrus species, such as Cedrus deodara', Salix species such as Salix sachalinensis ; as well as some Pinaceae. Of these, Hovenia dulcis and Ampelopsis grossedentata are preferred natural sources. The dihydromyricetin may conveniently be obtained or derived from the stems and / or leaves of such natural sources.

[0067]

[0033] Taxifolin is a pentahydroxyflavan-4-one having the structural formula (IB).

[0068]

[0069]

[0034] Taxifolin may also be referred to as (2R,3R)-3,3',4',5,7-Pentahydroxyflavan-4-one, as (2R,3R)-2-(3,4-Dihydroxyphenyl)-3,5,7-trihydroxy-2,3-dihydro-4 / - / -1-benzopyran-4-one, or as Dihydroquercetin.

[0070]

[0035] Taxifolin may conveniently be chemically or microbiologically produced or may be derived from a natural source, such as for example Larix sibirica, Pinus roxburghii and / or Cedrus deodara and / or Taxus chinensis.

[0071]

[0036] Aromadendrin is a tetrahydroxyflavan-4-one having the structural formula (IC).

[0072]

[0073] (IC)

[0074]

[0037] Aromadendrin may also be referred to as (2R,3R)-3,4',5,7-Tetrahydroxyflavan-4-one, as (2R,3R) -3,5,7-Trihydroxy-2-(4-hydroxyphenyl)-2,3-dihydro-4 / - / -1-benzopyran-4-one, or as Dihydrokaempferol.

[0075]

[0038] Aromadendrin may conveniently be chemically or microbiologically produced or may be derived from a natural source, such as for example Pinus sibirica.

[0076] THIOL-CONTAINING COMPOUND

[0077]

[0039] The thiol-containing compound may comprise one or more thiol groups. A thiol group is herein understood to be a “-S-H” group. Preferably the thiol-containing compound comprises one, two or three thiol groups, more preferably merely one or two thiol groups, most preferably merely one thiol group.

[0078]

[0040] In all aspects of the invention the thiol-containing compound is preferably an organosulfur compound having the form of R-SH, wherein R represents an organic substituent. Preferably the organic substituent R comprises in the range from 3 to 60 atoms, more preferably in the range 4 to 40 atoms.

[0041] Preferred thiol-containing compounds include alkyl thiols, thiol-containing amino acids and thiol-containing peptides. More preferably the thiol-containing compound in all aspects of the invention is a thiol-containing amino acid or a thiol-containing peptide.

[0079]

[0042] If the thiol-containing compound is an alkyl thiol, preferably the alkyl group comprises a total number of carbon atoms in the range from equal to or more than 2 to equal to or less than 60, more preferably in the range from equal to or more than 5 to equal to or less than 40. Preferred alkyl thiols include hexanethiol, octanethiol and dodecanethiol. These suitably have less of an undesirable smell. Dodecanethiol is especially preferred as an alkyl thiol as it is perceived as odorless.

[0080]

[0043] If the thiol-containing compound is a thiol-containing amino acid, preferably the thiol-containing amino acid is cysteine, homocysteine, N-acetyl cysteine and / or a mixture thereof.

[0081]

[0044] Most preferably the thiol-containing compound is a thiol-containing peptide. If the thiol-containing compound is a thiol-containing peptide, preferably the thiol-containing peptide is a dipeptide, tripeptide, tetrapeptide or pentapeptide, more preferably the thiol-containing peptide is a dipeptide, tripeptide or tetrapeptide, most preferably the thiol-containing peptide is a dipeptide or tripeptide. Preferably the thiol-containing peptide comprises one or more, more preferably one, two or three, cysteine and / or homocysteine amino acids. More preferably the thiol-containing peptide comprises or consists of glutamic acid (Glu), glutamine (Gin) , glycine (Gly), cysteine (Cys) and / or homocysteine (HCy) amino acids. Preferably the thiol-containing peptide is chosen from the group consisting of glutathione (also referred to as gamma-L-glutamyl-L-cysteinylglycine), cysteinylglycine (also referred to as L-cysteinyl-L-glycine), glutamylcysteine (also referred to as gamma-L-glutamyl-L-cysteine) and cysteinylcysteine (also referred to as L-cysteinyl-L-cysteine). Most preferably the thiol-containing peptide is glutathione.

[0082]

[0045] Preferably the thiol-containing compound is thus cysteine, homocysteine, N-acetyl cysteine, glutathione, cysteinylglycine, glutamylcysteine, cysteinylcysteine or a mixture of one or more thereof. Most preferably the thiol-containing compound is glutathione. Suchglutathione advantageously provides the best balance from an activity as well as an economic perspective.

[0083]

[0046] For the avoidance of doubt, preferably the thiol-containing compound is an amino acid and / or a peptide comprising a non-oxidized thiol group, most preferably a nonoxidized glutathione.

[0084]

[0047] Without wising to be bound to any kind of theory it is believed that non-oxidized glutathione, also sometimes referred to as “reduced” glutathione or abbreviated as “GSH”, is a tripeptide made of the amino acids glutamate, cysteine, and glycine, which may be active as an anti-oxidant; whilst oxidized glutathione, also sometimes abbreviated as “GSSG”, is formed when two glutathione (GSH) molecules have become linked together and represents the inactive used form.

[0085]

[0048] For practical purposes, the thiol-containing compound is preferably applied in any composition in an amount in the range from equal to or more than 0.01 wt. %, more preferably from equal to or more than 0.1 wt. % to equal to or less than 10 wt. %, more preferably to equal to or less than 3 wt. %, based on the total weight of the composition.

[0086] USE

[0087]

[0049] In a first aspect, the invention provides a use of thiol-containing compound for the stabilization of a flavanonol in a topical composition. Thus the invention provides a use of thiol-containing compound as a stabilizer for a flavanonol in a topical composition.

[0088]

[0050] Preferences for the flavanonol and the thiol-containing compound are as described above.

[0089]

[0051] More preferably the invention provides a use of a thiol-containing amino acid and / or a thiol-containing peptide for the stabilization of a flavanonol, preferably dihydromyricetin, in a topical composition. Thus, the invention provides a use of a thiol-containing amino acid and / or a thiol-containing peptide as a stabilizer for a flavanonol, preferably dihydromyricetin, in a topical composition.

[0090]

[0052] Preferably the thiol-containing compound, more preferably the thiol-containing amino acid and / or the thiol-containing peptide, is applied in a molar ratio of flavanonol tothiol-containing compound in the range from equal to or more than 1 :50 to equal to or less than 5:1 , more preferably in the range from equal to or more than 1 :10 to equal to or less than 2:1.

[0091]

[0053] Preferably the thiol-containing compound, more preferably the thiol-containing amino acid and / or the thiol-containing peptide, is applied in a weight ratio of flavanonol to thiol-containing compound in the range from equal to or more than 1 :50 to equal to or less than 5: 1 , more preferably in the range from equal to or more than 1 : 10 to equal to or less than 2:1.

[0092]

[0054] The thiol-containing compound, more preferably the thiol-containing amino acid and / or the thiol-containing peptide, may be applied by bringing it into contact with the flavanonol, for example by blending or mixing or by bringing both together in solution, emulsion or dispersion.

[0093]

[0055] Preferably the thiol-containing compound is contacted with the flavanonol by solving and / or dispersing both in a liquid. Preferably such liquid may comprise glycerol and / or water.

[0094]

[0056] Advantageously the invention also provides a method for contacting the thiol-containing compound with the flavanonol comprising the steps:

[0095] (i) solving, emulsifying or dispersing the flavanonol in a non-aqueous liquid, preferably glycerol;

[0096] (ii) solving, emulsifying or dispersing the thiol-containing compound in an aqueous liquid, preferably an aqueous buffer solution, more preferably an aqueous buffer solution having a pH in the range from equal to or more than 3.0 to equal to or less than 8.0, even more preferably an aqueous buffer solution having a pH in the range from equal to or more than 4.0 to equal to or less than 7.0, still more preferably an aqueous buffer solution having a pH in the range from equal to or more than 5.5 to equal to or less than 6.5, most preferably an aqueous buffer solution having a pH of about 6.0; and

[0097] (iii) contacting the non-aqueous liquid comprising the flavanonol with the aqueous liquid comprising the thiol-containing compound, preferably by blending or mixing;(iv) optionally adapting the pH of the blend or mixture to a pH in the range from equal to or more than 4.0 to equal to or less than 6.0, more preferably in the range from equal to or more than 4.5 to equal to or less than 5.5.

[0098]

[0057] In the above, the order of steps (i) and (ii) is arbitrary and step (i) may be carried out before, after or simultaneously with step (iii).

[0099]

[0058] The non-aqueous liquid, such as for example the glycerol, in step (i) may conveniently already comprise one or more helper ingredients (excipients) as further described herein.

[0100]

[0059] Also the aqueous liquid, such as for example the buffer solution, in step (ii) may conveniently already comprise one or more helper ingredients (excipients) as further described herein.

[0101] TOPICAL COMPOSITION

[0102]

[0060] In a second aspect, the invention provides a topical composition comprising a) a flavanonol; and

[0103] b) a thiol-containing compound,

[0104] wherein preferably the composition comprises the flavanonol and the thiol-containing compound in a molar ratio of flavanonol to thiol-containing compound in the range from equal to or more than 1 :50 to equal to or less than 5: 1.

[0105]

[0061] In addition, the invention provides a topical composition comprising

[0106] a) a flavanonol; and

[0107] b) a thiol-containing compound,

[0108] wherein preferably the composition comprises the flavanonol and the thiol-containing compound in a weight ratio of flavanonol to thiol-containing compound in the range from equal to or more than 1 :50 to equal to or less than 5: 1.

[0109]

[0062] More preferably the thiol-containing compound, more preferably the thiol-containing amino acid and / or the thiol-containing peptide, is present in a molar ratio of flavanonol to thiol-containing compound in the range from equal to or more than 1:10 to equal to or less than 2:1.

[0063] More preferably the thiol-containing compound, more preferably the thiol-containing amino acid and / or the thiol-containing peptide, is present in a weight ratio of flavanonol to thiol-containing compound in the range from equal to or more than 1:10 to equal to or less than 2:1.

[0110]

[0064] Preferences for the flavanonol and the thiol-containing compound are as described above.

[0111]

[0065] Preferably the topical composition comprises an amount of flavanonol, preferably an amount of dihydromyricetin in the range from equal to or more than 0.001 wt. %, more preferably from equal to or more than 0.01 wt. % to equal to or less than 10 wt. %, more preferably to equal to or less than 1 wt. %, based on the total weight of the composition.

[0112]

[0066] The application of the thiol-containing compounds advantageously renders the use of the undesired sulfites, meta-bisulfites, bisulfites and / or disulfites stabilizers obsolete. Preferably the topical composition therefore comprises a total amount of sulfites, metabisulfites, bisulfites and / or disulfites of equal to or less than 1.0 wt%, more preferably equal to or less than 0.1 wt%, even more preferably equal to or less than 0.01 wt% and most preferably equal to or less than 0.001 wt%, based on the total weight of the topical composition. More preferably the topical composition comprises no or essentially no sulfites, meta-bisulfites, bisulfites and / or disulfites. Most preferably the topical composition is free of sulfites, meta-bisulfites, bisulfites and / or disulfites.

[0113]

[0067] Preferably the topical composition is a cosmetic composition. More preferably the topical composition is a skin care composition, a sun care composition or a haircare composition. Most preferably the topical composition is a skin care composition. As explained below, suitably the topical composition can be applied in a variety of forms including for example as a gel, cream, ointment, lotion, serum, powder, spray, mask or two component dispensing system. Preferably the topical composition is applied in a spreadable form. Hence, preferably the topical composition is not applied in the form of a patch or a plaster. That is, preferably the topical composition is not, and is not part of, a patch or a plaster.

[0068] As explained herein above and herein below, the topical composition may comprise the flavanonol as an active ingredient. In accordance with the present invention, the topical composition according to the invention may also comprise further active ingredients conventionally used in topical, preferably cosmetic, compositions. Preferred additional active ingredients include: skin lightening agents, UV-filters, agents for the treatment of hyperpigmentation, agents for the prevention or reduction of inflammation, firming, moisturizing, soothing, and / or energizing agents as well as agents to improve elasticity and skin barrier.

[0114]

[0069] Preferably the topical composition comprises one or more UV filters. Preferred UV filters include Titanium Dioxide, Zinc Oxide, Benzophenone-3 (also referred to as Oxybenzone), Benzophenone-4 (also referred to as Sulisobenzone), Benzophenone-5, Butyl Methoxydibenzoylmethane (also referred to as Avobenzone), Ethylhexyl Methoxycinnamate (also referred to as Octinoxate), Ethylhexyl Salicylate (also referred to as Octisalate), Homosalate, Octocrylene, Terephthalylidene Dicamphor Sulfonic Acid, Drometrizole Trisiloxane, Bis-Ethylhexyloxyphenol Methoxyphenyl Triazine (also referred to as Bemotrizinol or “BEMT”), Methylene Bis-Benzotriazolyl Tetramethylbutylphenol (also referred to as Bisoctrizole, “MBBT”” ), Diethylamino Hydroxybenzoyl Hexyl Benzoate (also referred to as “DHHB”), Ethylhexyl Triazone (also referred to as “EHT”), Polysilicone-15, Isoamyl p-Methoxycinnamate, Phenylbenzimidazole Sulfonic Acid, Bisdisulizole Disodium, Tris-Biphenyl Triazine and / or combinations of one or more of these. Of these, homosalate, octocrylene, ethylhexyl salicylate, bis-ethylhexyloxyphenol methoxyphenyl triazine, butyl methoxydibenzoylmethane, Ethylhexyl triazone , Trisbiphenyl triazine and mixtures thereof are especially preferred.

[0115]

[0070] Preferably the topical composition comprises hyaluronic acid or a derivative thereof. More preferably the topical composition comprises hyaluronic acid, a hyaluronate salt, (such as for example sodium hyaluronate), hydrolyzed hyaluronic acid, cross-linked hyaluronic acid or any combination of one or more of these.

[0116]

[0071] In a preferred embodiment, the topical composition may preferably further comprise one or more vitamins or derivatives thereof selected from the group consistingof retionoids / carotene, preferably retinol (vitamin A), thiamin (vitamin B1), riboflavin (vitamin B2), niacin and / or niacinamide (vitamin B3), pantothenic acid (vitamin B5), pyridoxine (vitamin B6), cobalamin (vitamin B12), biotin, ascorbic acid (vitamin C), choline, calciferol (vitamin D), alpha-tocopherol (vitamin E), folic acid (vitamin B9), phylloquinone (vitamin K) and / or any combination thereof.

[0117]

[0072] In a preferred embodiment, the topical composition may preferably further comprise bakuchiol.

[0118]

[0073] In a preferred embodiment, the topical composition may preferably further comprise - for example as a senolytic agent - myricitrin and / or Epilobrium fleicheri extract.

[0119]

[0074] Conveniently the topical composition may comprise one or more further ingredients, also referred to herein as helper ingredients (excipients), including one or more carriers.

[0120]

[0075] More preferably the topical composition is a topical composition comprising a) a flavanonol; and

[0121] b) a thiol-containing compound; and

[0122] c) a carrier,

[0123] Preferences for such ingredients are as described above and below.

[0124]

[0076] Preferably the carrier is a cosmetically acceptable carrier. Preferred carriers include water and oils. Most preferably the carrier comprises water and / or glycerol.

[0125]

[0077] The composition according to the present invention can have a wide variety of forms. Non limiting examples include simple solutions (e.g. aqueous, organic solvent, or oil based), emulsion or micro emulsion (in particular of oil-in-water (O / W) or water-in-oil (W / O) type, silicone-in-water (Si / W) or water-in-silicone (W / Si) type, PIT-emulsion, multiple emulsion (e.g. of oil-in-water-in oil (O / W / O) or water-in-oil-in-water (W / O / W) type) or pickering emulsions), as well as solid forms (e.g. hydrogels, alcoholic gels, lipogels, sticks, flowable solids, or amorphous materials). These forms may be used for a number of applications, including, but not limited to, gels, creams, ointments, lotions, serums, powder, aerosol sprays or two component dispensing systems.

[0078] In a preferred embodiment, the compositions according to the present invention are emulsions and / or gels. Even more preferably, the compositions are emulsions which contain an oily phase and an aqueous phase such as in particular O / W, W / O, Si / W, W / Si, O / W / O, W / O / W multiple or a pickering emulsions.

[0126]

[0079] As indicated above, the flavanonol and the thiol-containing compound may advantageously be contacted with each other by means of blending or mixing a nonaqueous liquid and an aqueous liquid wherein such respective flavanonol and respective thiol-containing compound are advantageously dissolved, dispersed or emulsified.

[0127]

[0080] Therefore, the topical composition preferably comprises a solution, dispersion or emulsion comprising the flavanonol and a non-aqueous liquid. Preferably such nonaqueous liquid comprises:

[0128] - an oil or fat, such as for example almond oil, castor oil, coconut oil, groundnut oil, jojoba oil, olive oil, palm oil, rapeseed oil, soybean oil, sunflower oil, or a triglyceride, such as a capric or caprylic acid triglyceride, or any combination of one or more of these; and / or - an alcohol, diol, or polyol, preferably ethanol, isopropanol, ethylene glycol, propylene glycol, glycerol, or an ether or ester thereof, most preferably glycerol; and / or

[0129] - any combination of the above.

[0130]

[0081] In addition, the topical composition preferably comprises a solution, dispersion or emulsion comprising the thiol-containing compound and an aqueous liquid. Preferably such aqueous liquid comprises:

[0131] - water; and / or

[0132] - one or more surfactants; and / or

[0133] - one of more buffering ingredients such as an acid or a base.

[0134] In a preferred embodiment the aqueous liquid comprises citric acid or an aqueous citric acid solution.

[0135]

[0082] The topical compositions of the invention (including the carrier) may comprise further conventional (cosmetic) excipients, such as preservatives / antioxidants, fatty substances / oils, water, organic solvents, silicones, thickeners, softeners, emulsifiers, antifoaming agents, aesthetic components such as fragrances, aroma ingredients,surfactants, fillers, anionic, cationic, non-ionic or amphoteric polymers or mixtures thereof, propellants, acidifying or basifying agents, dyes, colourings / colorants, abrasives, absorbents, chelating agents and / or sequestering agents, essential oils, skin sensates, astringents, pigments or any other ingredients suitable for inclusion into such compositions.

[0136]

[0083] Of course, one skilled in this art will take care to select the above mentioned optional additional ingredients, adjuvants, diluents and additives and / or their amounts such that the advantageous properties intrinsically associated with the combination in accordance with the invention are not, or not substantially, detrimentally affected by the envisaged addition or additions.

[0137]

[0084] The topical compositions according to the present invention can advantageously be cosmetic skin care compositions, cosmetic sun care compositions and / or cosmetic hair care compositions. Preferred examples of such skin care compositions include creams, serums, exfoliating scrubs, masks, lotions, gels, sprays and balms.

[0138]

[0085] The topical composition can advantageously be a leave-on or rinse-off composition, preferably a leave-on composition.

[0139]

[0086] In a preferred embodiment the composition according to the inventions can be sold or advertised or otherwise named as an anti-aging composition or anti-aging product.

[0140]

[0087] Hence the invention also provides a topical composition for use in an anti-aging or epigenetic treatment of the skin, wherein the composition is comprising:

[0141] - dihydromyricetin, and

[0142] - a thiol-containing compound for stabilizing the dihydromyricetin, preferably non-oxidized glutathione.

[0143] Without wishing to be bound by any kind of theory it is believed that the improved stability of the dihydromyricetin in such a composition may advantageously allow for a lower concentration of dihydromyricetin to be used in the composition and / or a higher efficacy of such composition at the same concentration.

[0144]

[0088] For practical purposes, the topical composition may preferably comprise the thiol-containing compound in an amount in the range from equal to or more than 0.01 wt. %,more preferably from equal to or more than 0.1 wt. % to equal to or less than 10 wt. %, more preferably to equal to or less than 3 wt. %, based on the total weight of the composition.

[0145] DIHYDROMYRICETIN APPLICATION METHOD

[0146]

[0089] As illustrated by the examples, the above use and composition may advantageously lead to a better stability and less degradation of a flavanonol such as dihydromyricetin.

[0147]

[0090] As indicated before, dihydromyricetin may advantageously be used as an epigenetic agent.

[0148]

[0091] The above use and composition may therefore advantageously also better preserve efficacy of dihydromyricetin as an epigenetic active ingredient. Therefore, in a third aspect, the invention provides a method comprising the step of topically applying to a skin in need thereof a topical composition comprising:

[0149] - dihydromyricetin as an epigenetic active ingredient; and

[0150] - a thiol-containing compound.

[0151] Preferably such a method is a method for epigenetic treatment of a keratinous surface, preferably for epigenetic treatment of the skin.

[0152]

[0092] Preferences for the thiol-containing compound are as described above.

[0153]

[0093] Preferably the dihydromyricetin and the thiol-containing compound are applied in the method :

[0154] -in a molar ratio of dihydromyricetin to thiol-containing compound in the range from equal to or more than 1 :50 to equal to or less than 5:1 ; and / or

[0155] - in a weight ratio of dihydromyricetin to thiol-containing compound in the range from equal to or more than 1 :50 to equal to or less than 5:1.

[0156] Further preferences for such ratio’s are as described above.

[0157]

[0094] Preferably the dihydromyricetin is applied to the skin in an amount effective to prevent DNA-methylation, more preferably in an amount in the range from equal to or more than 0.001 wt. %, more preferably from equal to or more than 0.01 wt. % to equalto or less than 10 wt. %, more preferably to equal to or less than 1 wt. %, based on the total weight of the topical composition.

[0158]

[0095] In the below the invention is illustrated by the following non-limiting examples

[0159] EXAMPLES

[0160] Example 1 - preparation of Dihydromyricetin (DHM) solution in glycerol

[0161]

[0096] 1.013 g of Dihydromyricetin (DHM), 3.16 mmol) was dissolved to a total volume of 100 mL with glycerol.

[0162] Example 2 - preparation of stabilizer solution

[0163] Preparation of 0.025M Citric Acid Buffer

[0164]

[0097] 6.067 g (20.6 mmol) sodium citrate dihydrate and 839 mg citric acid (4.4 mmol) were dissolved in citric acid dissolved in 900 mL tap water. pH was adjusted to 6.0 with 2 M HCI and 2 M NaOH and the solution was diluted with tap water to 1000 mL.

[0165]

[0098] The amounts of the stabilizers shown in Table 1 were weighted into a graduated flask and dissolved with the above citric acid buffer to a volume of 100 mL

[0166] Table 1: preparation of stabilizer solutions

[0167] Stabilizer Amount [mg] Amount [mmol]

[0168] Ascorbic acid 75.2 0.43

[0169] Sodium metabisulfite 40.5 0.21*

[0170] Glutathione (non129.4 0.42

[0171] oxidized)

[0172] Cysteine 51.3 0.42

[0173]

[0174] *0.21 mmol sodium metabisulfite will lead to of 0.42 mmol sodium bisulfite upon contact with water.Example 3 - Solutions for stability assessment

[0175]

[0099] 10 mL of the DHM solution in glycerol (as prepared in example 1) and 90 mL of the respective solution of stabilizer in citric acid buffer (as prepared in example 2) were mixed (magnetic stirring) in a 100 mL clear glass screw cap bottle (Schott), resulting in a concentration of approx. 1 mg / mL DHM, and a DHM:stabilizer molar ratio of approx. 1:1.2. The solutions were stored in flasks and allowed to stand at 20-25 °C.

[0176]

[0100] At day 8 after preparation the colour of the solutions in the flasks was assessed by means of visual assessment and by means of a 3-D colour space L*a*b (CIELAB) assessment wherein:

[0177] L* determines whether a sample is bright (high L*) or dark (low L*). In the color space diagram, L* is represented by a vertical axis with values ranging from 0 (black) to 100 (white).

[0178] a* and b* indicate the sample's chromaticity (hue and chroma).

[0179] a* = red to green (+a = redder, -a = greener).

[0180] b* = yellow to blue. (+b = yellower, -b = bluer).

[0181] (The intersection of the two "color" axes yields neutral gray).

[0182]

[0101] The results are illustrated in figure 1 and Tables 2a and 2b

[0183] Table 2a: Colour of the solutions in figure 1 at day 8 after preparation

[0184] Flask Type of Stabilizer Colour (visual assessment)

[0185] 1 No stabilizer Transparent, dark yellow- orange

[0186] 2 Sodium bisulfite Transparent, yellow

[0187] 3 Glutathione (non-oxidized) Transparent, colorless

[0188] 4 Ascorbic acid Transparent, yellow

[0189] 5 Cysteine Transparent, beige

[0190]

[0191] Table 2b: Colour of the solutions in figure 1 at day 8 after preparation

[0192] Flask Type of Stabilizer L*a*b. dE*ab

[0193] 1 No stabilizer 94.47 / 0.12 / 19.94 20.70

[0194] 2 Sodium bisulfite 99.03 / -5.07 / 14.15 15.07

[0195] 3 Glutathione (non-oxidized) 99.27 / -1.53 / 3.78 4.16

[0196] 4 Ascorbic acid 98.38 / -2.44 / 10.29 10.71

[0197] 5 Cysteine 97.17 / -3.54 / 9.27 10.33

[0198]

[0199]

[0102] In addition the HPLC purity of the DHM was analyzed. The method applied for the HPLC purity analysis was as follows:

[0200] Waters Acquity Ultra Performance Liquid Chromatography system (U-HPLC), equipped with an Acquity HSS T3 100 A 1.8pm 2.1 x50 mm2 analytical column and a PDA detector operating in the 200-400 nm wavelength range. H2O + 0.02 % TFA (A phase) and MeCN + 0.02 % TFA (B phase) were used as eluents, with a flow of 0.5 mL / min. Samples were injected without dilution. Gradient: 2% B - 7 min - 100% B - 2.5min - 100% B.

[0201]

[0103] The results of the purity assessment at day 8 after preparation are provided in Table 3

[0202] Table 3: DHM Purity at day 8 after preparation

[0203] %a DHM at 292 nm, sum of Isomers

[0204] No stabilizer 93.43

[0205] Sodium bisulfite 95.03

[0206] Glutathione (non-oxidized) 98.72

[0207] Ascorbic acid 90.36

[0208] Cysteine 97.93

[0209]

Claims

CLAIMS1. A use of a thiol-containing compound for the stabilization of a flavanonol in a topical composition, preferably a composition for use on keratinous tissue such as the skin, scalp or hair.

2. The use according to claim 1 , wherein the flavanonol is Dihydromyricetin, Taxifolin and / or Aromadendrin, preferably wherein the flavanonol is Dihydromyricetin.

3. A use of a thiol-containing compound for stabilizing dihydromyricetin in a topical composition for epigenetic treatment of the skin, preferably wherein the topical composition comprises an amount of dihydromyricetin in the range from equal to or more than 0.001 wt. %, more preferably from equal to or more than 0.01 wt. % to equal to or less than 10 wt. %, more preferably to equal to or less than 1 wt. %, based on the total weight of the composition.

4. The use according to any one of the preceding claims, wherein the thiol-containing compound is an alkyl thiol, thiol-containing amino acid and / or a thiol-containing peptide, more preferably wherein the thiol-containing compound is thiol-containing amino acid and / or a thiol-containing peptide, most preferably wherein the thiol- containing compound is a thiol-containing peptide.

5. The use according to any one of the preceding claims, wherein the thiol-containing compound is a thiol-containing peptide, wherein the thiol-containing peptide comprises or consists of glutamic acid (Glu), glutamine (Gin) , glycine (Gly), cysteine (Cys) and / or homocysteine (HCy) amino acids.

6. The use according to any one of the preceding claims, wherein the thiol-containing compound is cysteine, homocysteine, N-acetyl cysteine, glutathione, cysteinylglycine, glutamylcysteine, cysteinylcysteine or a mixture thereof, more preferably wherein the thiol-containing compound is non-oxidized glutathione.

7. The use according to any one of the preceding claims, wherein the molar ratio of flavanonol to thiol-containing compound is in the range from equal to or more than 1:50 to equal to or less than 5:1, more preferably in the range from equal to or more than 1 : 10 to equal to or less than 2:1.

8. The use according to any one of the preceding claims, wherein the weight ratio of flavanonol to thiol-containing compound is in the range from equal to or more than 1:50 to equal to or less than 5:1, more preferably in the range from equal to or more than 1 : 10 to equal to or less than 2: 1.

9. Atopical composition comprisinga) a flavanonol; andb) a thiol-containing compound,wherein preferably the topical composition comprises the flavanonol and the thiol- containing compound in a molar ratio of flavanonol to thiol-containing compound in the range from equal to or more than 1 :50 to equal to or less than 5:1 ; and / or wherein preferably the topical composition comprises the flavanonol and the thiol- containing compound in a weight ratio of flavanonol to thiol-containing compound in the range from equal to or more than 1 :50 to equal to or less than 5:1.

10. The topical composition according to claim 9, wherein the flavanonol is Dihydromyricetin, Taxifolin and / or Aromadendrin, preferably wherein the flavanonol is Dihydromyricetin.

11. The topical composition according to claim 9 or 10, wherein the thiol-containing compound is cysteine, homocysteine, N-acetyl cysteine, glutathione, cysteinylglycine, glutamylcysteine, cysteinylcysteine or a mixture thereof, more preferably wherein the thiol-containing compound is non-oxidized glutathione.

12. The topical composition according to any one of claims 9 to 11 , wherein the topical composition further comprises one or more UV filters; and / or hyaluronic acid or a derivative thereof.

13. The topical composition according to any one of claims 9 to 12, wherein the topical composition comprises no or essentially no sulfites, meta-bisulfites, bisulfites and / or disulfites.

14. A method comprising the step of topically applying to a skin in need thereof a topical composition comprising:- dihydromyricetin as an epigenetic active ingredient; and- a thiol-containing compound.

15. A method for contacting the thiol-containing compound with the flavanonol comprising the steps:(i) solving, emulsifying or dispersing the flavanonol in a non-aqueous liquid, preferably glycerol;(ii) solving, emulsifying or dispersing the thiol-containing compound in an aqueous liquid, preferably an aqueous buffer solution, more preferably an aqueous buffer solution having a pH in the range from equal to or more than 3.0 to equal to or less than 8.0 ; and(iii) contacting the non-aqueous liquid comprising the flavanonol with the aqueous liquid comprising the thiol-containing compound, preferably by blending or mixing; and(iv) optionally adapting the pH of the blend or mixture to a pH in the range from equal to or more than 4.0 to equal to or less than 6.0, more preferably in the range from equal to or more than 4.5 to equal to or less than 5.5.